You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market Plan access at approximately 200 million lives — 87% commercial and 35% Medicare Male Osteo Trial: FDA agreement on the design of a clinical trial in men FDA Fast Track Designation for
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc.
Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing and
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m.
WALTHAM, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today
ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate WALTHAM, Mass., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to
WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today
Results from the ACTIVExtend trial, which demonstrated statistically significant fracture risk reduction at 3.5 years of sequential therapy — TYMLOS followed by alendronate — will be presented in an Oral Plenary Session Company plans to submit the ACTIVExtend results to the FDA by year
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bone Health WALTHAM,